Extranodal presentation in limited-stage diffuse large Bcell lymphoma as a prognostic marker in three SWOG trials S0014, S0313 and S1001
Haematologica
.
2022 Nov 1;107(11):2732-2736.
doi: 10.3324/haematol.2022.281004.
Authors
Deborah M Stephens
1
,
Hongli Li
2
,
Louis S Constine
3
,
Thomas J Fitzgerald
4
,
John P Leonard
5
,
Brad S Kahl
6
,
Joo Y Song
7
,
Michael L LeBlanc
2
,
Sonali M Smith
8
,
Daniel O Persky
9
,
Jonathan W Friedberg
10
Affiliations
1
Division of Hematology, University of Utah, Salt Lake City. Deborah.stephens@hci.utah.edu.
2
SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Research Center, Seattle.
3
Departments of Radiation Oncology and Pediatrics, University of Rochester, Rochester.
4
Imaging and Radiation Oncology Core (IROC), Lincoln, RI.
5
Division of Hematology and Medical Oncology, Weill Cornell Medical Center, New York.
6
Department of Medicine, Washington University School of Medicine, St. Louis, MO.
7
Department of Pathology, City of Hope, Duarte, CA.
8
Section of Hematology/Oncology, University of Chicago, Chicago, IL.
9
Division of Hematology/Oncology, University of Arizona, Tucson, AZ.
10
Division of Hematology/Oncology, University of Rochester, Rochester.
PMID:
35833300
PMCID:
PMC9614528
DOI:
10.3324/haematol.2022.281004
No abstract available
MeSH terms
Antineoplastic Combined Chemotherapy Protocols
Humans
Lymphoma, Large B-Cell, Diffuse* / pathology
Lymphoma, Non-Hodgkin*
Prognosis
Vincristine / therapeutic use
Substances
Vincristine
Grants and funding
UG1 CA233230/CA/NCI NIH HHS/United States
UG1 CA233178/CA/NCI NIH HHS/United States
U10 CA180821/CA/NCI NIH HHS/United States
U10 CA180882/CA/NCI NIH HHS/United States
U10 CA180820/CA/NCI NIH HHS/United States
U10 CA180888/CA/NCI NIH HHS/United States
U10 CA180819/CA/NCI NIH HHS/United States
UG1 CA233339/CA/NCI NIH HHS/United States